Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LMNA | P02545 | 1/20 | 0.48 |
| ▸ | GAA | P10253 | 1/20 | 0.48 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.40 |
| ▸ | HTT | P42858 | 1/20 | 0.40 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.38 |
| ▸ | MTNR1A | P48039 | 8/20 | 0.37 |
| ▸ | PTGDR2 | Q9Y5Y4 | 1/20 | 0.37 |
| ▸ | MTNR1B | P49286 | 8/20 | 0.37 |
| ▸ | NQO2 | P16083 | 6/20 | 0.37 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.36 |
| ▸ | SIGMAR1 | Q99720 | 1/20 | 0.36 |
| ▸ | ATM | Q13315 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL19635311 | 0.85 | PTGDR2 (0.34) | LMNAGAASMN1; SMN2PTGDR2ATM | |
| SCHEMBL5477645 | 0.84 | MAPT (0.40) | LMNAGAASMN1; SMN2MTNR1AMTNR1B | |
| SCHEMBL5477650 | 0.84 | MAPT (0.40) | LMNAGAASMN1; SMN2MTNR1AMTNR1B | |
| SCHEMBL5485146 | 0.84 | MEN1 (0.37) | PTGDR2 | |
| SCHEMBL5482888 | 0.84 | KMT2A (0.36) | LMNAGAAHTTSMN1; SMN2PTGDR2 | |
| SCHEMBL19635324 | 0.81 | PTGDR2 (0.38) | LMNAGAAPTGDR2 | |
| SCHEMBL10467454 | 0.81 | KDM4E (0.48) | LMNAGAAKDM4EHTTALDH1A1 | |
| SCHEMBL29602500 | 0.80 | ALDH1A1 (0.39) | LMNAKDM4EHTTALDH1A1 | |
| SCHEMBL19615288 | 0.75 | CYP11B1 (0.31) | — | |
| SCHEMBL6787435 | 0.74 | KDM4E (0.49) | LMNAGAAKDM4EHTTALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20070185323-A1 | Method of preparing benzazepines and derivatives thereof | ECOLE POLYTECHNIQUE (FR) | 2007-08-09 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070185323-A1 | Method of preparing benzazepines and derivatives thereof | CYP2F1, MAOB, CYP1A2 | LMNA 705/4885GAA 2016/4885KDM4E 1018/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.